Sonnet Biotherapeutics Holdings Stock Predictions

Healthcare > Biotechnology

Buy SONN

*Your capital is at risk

$1.26

+0 (+0%)

At Close: Feb 27, 2026

Currently predicting for Wed, 15 Jul 2026

SONN Live board

Community Bull/Bear

Target Next close

Join the SONN prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

SONN Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For SONN

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

SONN Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT SONNET BIOTHERAPEUTICS HOLDINGS INC.

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	10.58%	Jun 29
NMRK $15.02	0.466%	Jun 24
X XMAX $8.34	2.40%	Jun 24
NESR $25.07	12.49%	Jun 23
CAG $13.43	6.70%	Jun 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by